Hormonal
Acute damaging muscle-lengthening contractions trigger a temporal sequence of IGF-1 splice variant expression in human skeletal muscle, where Mechano Growth Factor (MGF) peaks early (24h) correlating with satellite cell proliferation markers (Myf5/MyoD), while IGF-1Ea and IGF-1Eb peak later (72h) correlating with differentiation markers (MRF4/myogenin).
This research highlights that muscle repair after intense exercise (like heavy eccentric training) relies on local molecular signals rather than blood hormone levels. Specifically, the body produces a variant called MGF early on (around 24 hours) to kickstart satellite cell proliferation, followed by other IGF variants (Ea/Eb) later (around 72 hours) to help cells differentiate and repair. For training, this implies that sufficient mechanical damage is required to trigger this specific local molecular cascade, and that recovery time allows these distinct phases to occur.
These results suggest that the temporal response of MGF is probably related to the activation/proliferation phase of the myogenic programme as marked by an increase in both Myf5 and MyoD, while IGF-1Ea and -Eb may be temporally related to differentiation as marked by an increase in MRF4 and myogenin expression following acute muscle damage.
Why this rating
Small sample size (n=8) and single-session acute response design limit generalizability to chronic adaptations, but the mechanistic clarity is high.
Source
Co‐expression of IGF‐1 family members with myogenic regulatory factors following acute damaging muscle‐lengthening contractions in humans
Bryon R. McKay et al. · The Journal of Physiology · 2008
DOI 10.1113/jphysiol.2008.160176
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →